Table 5.
Relative risk reduction (RRR, %) between treatments (teriparatide versus placebo) for morphometric vertebral fractures at different T-score values of BMD
Percentile | BMD | RRR | |
---|---|---|---|
Estimate | 95 % CI | ||
10th | −3.7 | 49 % | 0–86 %a |
25th | −3.3 | 73 % | 17–81 % |
50th | −2.8 | 88 % | 50–97 % |
75th | −2.4 | 94 % | 57–99 % |
90th | −2.0 | 97 % | 61–100 % |
a95 % CI relative risk fracture teriparatide versus placebo = 0.14–1.81